Diez años atrás, Kristin Kramer se despertó temprano una mañana porque uno de sus perros necesitaba salir. Fue cuando sucedieron un par de cosas extrañas. Cuando intentó llamar a su otro perro, “no podía hablar”, recordó. Y al bajar las escaleras para dejarlos salir al jardín, “me di cuenta que no podía mover mi mano…
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. Clarifying the FDA’s Role and Authority Over Direct-to-Consumer Drug Ads While several inaccuracies in the recent opinion piece about direct-to-consumer prescription drug advertisements by KFF Health News’ Elisabeth Rosenthal have been…
Every day for nearly 18 years, Alessandra Fabrello has been a medical caregiver for her son, on top of being his mom. “It is almost impossible to explain what it takes to keep a child alive who should be dead,” said Fabrello, whose son, Ysadore Maklakoff, experienced a rare brain condition called acute necrotizing encephalopathy…
The challenge is not just to minimize harm, but to make choices that expand human flourishing rather than reduce us to more efficient workers or more predictable consumers. The post The Ethical Frontiers of Brain-Computer Interfaces appeared first on MedCity News.
To be eligible qualify for the FDA’s new Commissioner’s National Priority Voucher program, a drug must meet certain national health interests. Qualifying medicines could be reviewed in one to two months, down from the standard 10 months to a year. The post FDA Pilot Program Shortens Drug Reviews; ‘We Have Got to Modernize the Agency,’…
“We’re done with junk science,” RFK Jr. said in a news conference on Thursday
Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene therapy and cardiometabolic disease. The plans follow U.S. capital expenditure announcements from several big pharmaceutical companies. The post Roche Commits to $50B in U.S. Manufacturing and R&D Investments as Pharma Tariffs Loom appeared first on…
If you get sick in America, there’s a good chance you’ll end up in debt. Four in 10 U.S. adults have some form of health-care debt, KFF has found. One surprising risk: living in a community where hospitals have consolidated — an increasingly common development as health systems merge or large systems gobble up smaller hospitals. That’s…
Expert notes that insurance coverage remains poor for obesity as a medical condition
Kura Oncology’s Komzifti is approved for treating advanced cases of acute myeloid leukemia with an NPM1 mutation. A Syndax Pharmaceuticals drug is already approved in this indication, but Kura says its drug has advantages in safety and patient convenience. The post FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma appeared first…